Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma
Gut and Liver
;
: 343-351, 2013.
Article
in English
| WPRIM
| ID: wpr-158230
ABSTRACT
BACKGROUND/AIMS:
This study reports treatment outcomes after helical intensity-modulated radiotherapy (IMRT) in unresectable hepatocellular carcinoma (HCC) patients for whom transarterial chemoembolization (TACE) was considered ineffective or unsuitable.METHODS:
From January 2008 to December 2011, 22 unresectable HCC patients received helical IMRT. A daily dose of 1.8 to 4 Gy was delivered at five fractions per week to deliver a total dose of 30 to 60 Gy. The most-prescribed dose fractionation was a total dose of 50 to 57.5 Gy, with a daily dose of 2.3 to 2.5 Gy.RESULTS:
In the entire group, the objective response rate of the primary tumor was 72.7%. In the eight patients with portal vein thrombosis (PVT), the objective response rate of PVT was 50.0%. Median disease progression-free survival was 11.8 months, and the 1-year disease progression-free survival rate was 40.2%. The median overall survival was 14.4 months, and the 1- and 2-year overall survival rates were 86.4% and 69.1%, respectively. PVT and Child-Pugh classifications were significant prognostic factors for overall survival in multivariate analyses.CONCLUSIONS:
Helical IMRT in patients with unresectable HCC resulted in high treatment response and survival rates. This study suggests helical IMRT is a practical treatment option for HCC patients in whom TACE is unsuitable or ineffective.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Portal Vein
/
Thrombosis
/
Survival Rate
/
Carcinoma, Hepatocellular
/
Disease-Free Survival
/
Dose Fractionation, Radiation
/
Radiotherapy, Intensity-Modulated
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS